In this first half, IPOs surpassed the mid-pandemic level in value. Many stocks that have recently been listed could be affected by the Fed’s plans to tighten its monetary policy in late May. Inflation is also rising. We think that it is best not to list the IPO stocks Amplitude, Dutch Bros and Tyra Biosciences. They are overvalued at current prices. Let’s discuss.For the first half of this year, initial public offerings (IPOs) hit record highs, totaling $171 billion and surpassing the IPO boom of 2020. The boom was primarily driven by loose monetary policies. Investors rushed to get in on the speculative thrill, driving corporate valuations much higher. It is unlikely that the IPO trend will slow. Renaissance Capital, a Frontier Markets investment bank, anticipates that the year will conclude with 600 traditional IPOs as well as 600 SPACs.

Investing in IPOs may be risky as there is not much historical information on the companies that list the stock. In addition, the Fed plans to decrease its monthly bond purchases this month. It is taking the first steps in reducing its monetary assistance. The central bank’s bond-buying is expected to decline by $15 billion each month. Inflation worries are also a persistent concern due to supply chain issues. This could negatively impact many stocks recently listed.

At their current price level, recently listed stocks Amplitude, Inc., Dutch Bros Inc., (BROS) and Tyra Biosciences, Inc., (TYRA), look highly overpriced. These stocks could be avoided at this time, according to our opinion.

Continue reading on StockNews